PHARMARESEARCH BIO Co. Ltd.

As of December 31, 2025, PHARMARESEARCH BIO Co. Ltd. carries a market capitalization of 132.11B, placing it among publicly traded companies globally. Its enterprise value stands at 122.92B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, PHARMARESEARCH BIO Co. Ltd. has 4.18M shares outstanding.

As of December 31, 2025, PHARMARESEARCH BIO Co. Ltd. trades at a trailing price-to-earnings ratio of 10.57. The price-to-sales ratio is 4.19, and the price-to-book ratio stands at 2.29.

As of December 31, 2025, PHARMARESEARCH BIO Co. Ltd. trades at an EV/EBITDA multiple of 8.02 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.95 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 8.95 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. PHARMARESEARCH BIO Co. Ltd. trades at an EV/FCF ratio of 775.14, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 122.92B versus a market cap of 132.11B, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, PHARMARESEARCH BIO Co. Ltd. maintains a current ratio of 1.09, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 59.85, indicating elevated leverage, while an interest coverage ratio of 10.18 demonstrates strong ability to service its debt obligations.

Over the twelve months ended December 31, 2025, PHARMARESEARCH BIO Co. Ltd. posted a return on equity (ROE) of 24.54, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 13.98 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 12.90, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.35, useful for judging operating efficiency across full business cycles. The company generates approximately 301.82M in revenue per employee across its workforce of 103.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.75 indicates how many times PHARMARESEARCH BIO Co. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2025, PHARMARESEARCH BIO Co. Ltd. recorded 1.98B in income tax expense. That works out to an effective tax rate of 13.84, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 14.31B, leaving 12.33B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, PHARMARESEARCH BIO Co. Ltd.'s stock has declined approximately 10.28% over the past 52 weeks. The 50-day moving average sits at 30,284.00, while the 200-day moving average is 32,495.50.

Over the twelve months ended December 31, 2025, PHARMARESEARCH BIO Co. Ltd. generated 31.09B in revenue and converted that into 12.33B in net income, yielding earnings per share of 2,054.52. EBITDA reached 15.33B, while operating income came in at 13.73B.

As of December 31, 2025, PHARMARESEARCH BIO Co. Ltd. holds 43.68B in cash and equivalents against 34.48B in total debt, resulting in a net debt position of 25.45B. Total book value stands at 57.62B, with working capital of 4.12B providing operational flexibility.

PHARMARESEARCH BIO Co. Ltd. produced 13.43B in operating cash flow over the twelve months ended December 31, 2025. After subtracting -14.57B in capital expenditures, free cash flow totaled -1.14B - equivalent to -276.06 per share.

Over the twelve months ended December 31, 2025, PHARMARESEARCH BIO Co. Ltd. posted a gross margin of 70.11, reflecting its pricing power and cost economics. The operating margin of 44.18 and net profit margin of 39.66 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -0.60: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.14, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to PHARMARESEARCH BIO Co. Ltd. shareholders.

As of December 31, 2025, PHARMARESEARCH BIO Co. Ltd. has an Altman Z-Score of 2.75, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.